American Technion Society

Cancer Patients May Not Have Higher COVID-19 Risk

17-Sep-2020 2:05 PM EDT, by American Technion Society

Newswise — A first-of-its-kind study examining the assumption that cancer patients are an at-risk group for COVID-19 finds that these patients do not get infected any more than the general population and do not suffer from more severe disease symptoms. In fact, based on their findings, the researchers hypothesize that cancer treatments may affect the patients’ response to COVID19-induced "cytokine storm."

From the moment the COVID-19 pandemic broke out, medical teams around the world operated under the assumption that cancer patients were an at-risk group in terms of contracting the virus. Defining cancer patients as an at-risk group had far-reaching implications for their treatment - this without any prior scientific basis. Patients were afraid to seek treatment for fear of contracting the coronavirus in hospitals, and in some countries, guidelines were issued for postponing oncology treatments in certain situations.

A new study conducted by researchers at Rambam Medical Center and the Technion reveals surprising findings, namely that cancer patients may not be associated with the broad range of at-risk groups of people suffering from morbidities. The research was led by Professor Yuval Shaked, head of the Rappaport - Technion Integrated Cancer Center (R-TICC) and Professor Irit Ben Aharon, director of the Division of Oncology at Rambam and principal investigator at the R-TICC, in collaboration with Dr. Tal Goshen-Lago, head of the Translational Research Division of Oncology at Rambam. The findings were published in Cancers, in a special edition dealing with the impact of the coronavirus on cancer patients.

The study included 271 participants, including 164 cancer patients, who came to the Rambam Medical Center to receive ongoing treatment for their disease, and a control group of 107 healthy employees among the medical staff. In the study, which was conducted between March and June 2020, all participants underwent blood tests, at three different times, to examine changes in the profile of the immune system. The test monitored three antibodies - IgG, IgM and IgA - that represent antibody formation at different times of virus exposure.

“We were surprised to find that cancer patients and health subjects developed antibodies at similar rates,” said Prof. Ben Aharon. "2.4% of cancer patients who participated in the study and 1.9% of participants in the healthy control group developed antibodies for the coronavirus and all were asymptomatic. Moreover, throughout the entire study period, no symptomatic coronavirus patients were detected in the study population and among the general population of our oncology patients." According to Prof. Ben Aharon, the CyTOF technology was used to map immune system cells, and a significant difference was found between the immune profile of cancer patients who were positive for coronavirus antibodies and the immune profile of the positive staff members.

"Our hypothesis is that the different response of cancer patients to the disease is related to the fact that anti-cancer treatment changes the profile of the immune system,” said Prof. Shaked. “The myeloid cells, which are vital cells in the immune system, are severely damaged by the coronavirus. In the general population and in the medical staff that participated in the study, the virus reduces the rate of myeloid cells by about 90%; in cancer patients, however, it reduces them by only 50%. This fact gives cancer patients relative protection.”

Prof. Ben Aharon added that the hypothesis is that anti-cancer treatments may change the profile of the immune system and its function which may limit the ability of the coronavirus to induce severe inflammation in patients receiving these treatments. The researchers estimate that this is why the proportion of cancer patients with non-hematological malignancies who develop severe disease is relatively low compared to that of the general population according to the literature, and that severity may be affected by other comorbidities. The mechanism for this observation is being further explored nowadays.

The research was supported by the Israel Cancer Research Fund (ICRF) and the European Research Council (ERC grant).

Prof. Irit Ben Aharon is a doctor and researcher and head of the Oncology Department at the Rambam Health Care Campus.

Prof. Yuval Shaked is head of the Technion Integrated Cancer Center in the Rappaport Faculty of Medicine (R-TICC). The center, established in 2016, promotes research that combines basic, clinical and engineering science in favor of developing new tools for cancer diagnosis, treatment and follow-up.

For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.

The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5594
Released: 10-May-2021 1:55 PM EDT
O filtro HEPA reduz as partículas respiratórias transportadas pelo ar geradas durante exercícios intensos
Mayo Clinic

Aerossóis respiratórios são um componente comum da respiração e são uma forma comum de vírus respiratórios, como o COVID-19 , se espalharem para outras pessoas e superfícies. Os pesquisadores que realizam testes de esforço físico para pacientes cardíacos na Mayo Clinic descobriram que praticar exercícios em níveis crescentes de esforço aumentava a concentração de aerossol no ambiente ao redor. Eles também descobriram que um filtro de ar particulado de alta eficiência (HEPA) filtrou de forma eficaz os aerossóis e diminuiu o tempo necessário para limpar o ar entre os pacientes.

access_time Embargo lifts in 2 days
Embargo will expire: 12-May-2021 12:05 AM EDT Released to reporters: 10-May-2021 1:15 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-May-2021 12:05 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 10-May-2021 1:05 PM EDT
El filtro HEPA reduce las partículas respiratorias transmitidas por el aire que se generan durante el ejercicio intenso
Mayo Clinic

Los aerosoles respiratorios son un componente común de la respiración y constituyen una vía común de propagación de virus respiratorios como la COVID-19 a personas y superficies. Los investigadores que realizan pruebas de esfuerzo físico en pacientes con problemas cardíacos en Mayo Clinic hallaron que el ejercicio a niveles mayores de esfuerzo aumentaba la concentración de aerosoles en el entorno circundante. Además, descubrieron que el filtro recogedor de partículas de alta eficiencia (HEPA, por sus siglas en inglés) descartaba de manera eficaz los aerosoles y disminuía el tiempo necesario para purificar el aire entre los pacientes.

Newswise:Video Embedded spray-protocol-increases-delivery-of-antiseptic-to-prevent-covid-19
VIDEO
Released: 10-May-2021 12:55 PM EDT
Spray protocol increases delivery of antiseptic to prevent COVID-19
South Dakota State University

A trip to visit family in India gave an SDSU researcher a unique opportunity to improve delivery of an antiseptic nasal spray to help prevent COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 12-May-2021 5:00 AM EDT Released to reporters: 10-May-2021 10:25 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-May-2021 5:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 17-May-2021 10:00 AM EDT Released to reporters: 10-May-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 17-May-2021 10:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 17-May-2021 3:30 PM EDT Released to reporters: 10-May-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 17-May-2021 3:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 19-May-2021 1:30 PM EDT Released to reporters: 10-May-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2021 1:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 16-May-2021 8:00 AM EDT Released to reporters: 10-May-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 16-May-2021 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 14-May-2021 8:00 AM EDT Released to reporters: 10-May-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-May-2021 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 5594

close
1.37848